Tirzepatide for Sleep Apnea: Can It Replace Your CPAP?

SURMOUNT-OSA Trial Results

The SURMOUNT-OSA trial was a landmark phase 3 clinical program consisting of two parallel randomized, double-blind, placebo-controlled trials. Study 1 enrolled patients with moderate to severe OSA who were not currently using positive airway pressure (PAP) therapy. Study 2 enrolled patients with moderate to severe OSA who were using CPAP at baseline. All participants had a BMI of 30 or higher and an AHI of 15 or higher confirmed by polysomnography.

Participants were randomized to tirzepatide (escalated to the maximum tolerated dose up to 15 mg weekly) or placebo for 52 weeks. The primary endpoint was the change in AHI from baseline to week 52. In Study 1 (non-CPAP users), tirzepatide reduced AHI by an average of 25.3 events per hour compared to 5.3 events per hour with placebo — a treatment difference of approximately 20 events per hour. In Study 2 (CPAP users), tirzepatide reduced AHI by an average of 29.3 events per hour compared to 5.5 with placebo. These reductions corresponded to approximately 55 to 63 percent improvement from baseline AHI.

Several secondary endpoints were equally impressive. Oxygen desaturation index (the number of oxygen drops per hour) improved substantially. Daytime sleepiness, measured by the Epworth Sleepiness Scale, showed clinically meaningful improvement. Body weight decreased by an average of 18 to 20 percent with tirzepatide versus approximately 1.5 percent with placebo. Patient-reported outcomes including sleep quality, physical function, and quality of life all improved significantly. For an overview of tirzepatide's weight loss data across all trials, see our article on tirzepatide weight loss results.

Perhaps most striking, approximately 43 to 52 percent of tirzepatide-treated participants achieved an AHI below 15 events per hour — the threshold separating mild from moderate OSA — compared to only 14 to 16 percent with placebo. Some participants achieved an AHI below 5 events per hour, which is considered normal and below the diagnostic threshold for any degree of sleep apnea. This degree of resolution was previously only achievable through bariatric surgery in clinical practice.

FDA Approval of Zepbound for OSA: What It Means

In December 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, making it the first pharmaceutical therapy ever approved specifically for this indication. This approval is historically significant — for decades, the only FDA-cleared treatments for OSA were devices (CPAP, BiPAP, oral appliances, hypoglossal nerve stimulators) and surgical procedures (uvulopalatopharyngoplasty, maxillomandibular advancement). A medication that treats the underlying cause of obesity-related OSA fundamentally changes the treatment paradigm.

The approval opens several important clinical pathways. First, patients who cannot tolerate CPAP — estimated at 30 to 50 percent of those prescribed it — now have an evidence-based treatment alternative. Second, patients who decline CPAP because of lifestyle concerns, travel difficulties, or personal preference have a viable option. Third, the approval may improve insurance coverage for tirzepatide in patients with documented OSA, potentially providing an additional coverage pathway beyond the obesity and diabetes indications.

It is important to understand what the approval does and does not mean. The approval indicates that the FDA reviewed the SURMOUNT-OSA data and concluded that tirzepatide's benefits for OSA outweigh its risks in the indicated population. It does not mean that tirzepatide replaces CPAP for all patients, that every OSA patient will respond equally, or that tirzepatide eliminates the need for sleep medicine follow-up. The approval specifically applies to patients with moderate to severe OSA (AHI 15 or higher) and a BMI of 30 or higher — patients with milder OSA or normal-weight OSA are not covered by this indication.

How Tirzepatide Reduces Sleep Apnea: The Mechanisms

Understanding the biological mechanisms by which tirzepatide improves OSA explains why the clinical results are so substantial and helps predict which patients are most likely to benefit. The primary mechanism is mechanical: reduction of pharyngeal fat deposits that narrow the upper airway.

The pharynx — the region of the throat behind the nose and mouth — is surrounded by muscles and soft tissue that maintain airway patency during waking hours. During sleep, muscle tone decreases throughout the body, including in the pharyngeal muscles. In patients with excess pharyngeal fat, this loss of muscle tone allows the heavy, fat-laden tissue to collapse inward, obstructing airflow. MRI and CT studies have shown that even modest reductions in pharyngeal fat volume — approximately 10 to 15 percent — can significantly increase airway cross-sectional area and reduce the critical closing pressure of the airway.

Tirzepatide produces weight loss of 18 to 22 percent on average, which includes significant reductions in both visceral and regional fat deposits including the pharyngeal region. Studies using MRI to assess body composition during GLP-1 therapy have confirmed preferential reduction of visceral fat and ectopic fat deposits. The correlation between neck circumference reduction and AHI improvement is strong, supporting the mechanical unloading hypothesis as the primary driver of tirzepatide's OSA benefit.

Beyond the mechanical effect, tirzepatide improves OSA through secondary pathways. Reduction of abdominal fat relieves upward pressure on the diaphragm, increasing functional residual capacity (lung volume at rest) and improving the tracheal traction that helps hold the upper airway open. Decreased systemic inflammation reduces upper airway mucosal edema that contributes to narrowing. Improved insulin sensitivity and metabolic health may reduce the neuromuscular dysfunction that impairs pharyngeal muscle responsiveness in obese patients. For details on tirzepatide's mechanism of action, see our article on how tirzepatide works.

CPAP Adherence: Why Many Patients Want Alternatives

To understand why the approval of tirzepatide for OSA is so clinically impactful, it helps to appreciate the scope of the CPAP adherence problem. Medicare defines CPAP adherence as using the device for at least 4 hours per night on at least 70 percent of nights — a relatively low bar. Even with this generous definition, approximately 30 to 50 percent of patients fail to meet adherence criteria within the first 90 days. Long-term adherence rates are even lower.

The barriers to CPAP adherence are multiple and often interconnected. Mask discomfort and air leaks are the most commonly cited complaints. Nasal congestion, dry mouth, and aerophagia (swallowing air leading to bloating) are frequent side effects. Claustrophobia affects a significant minority of patients. The practical burden of traveling with a CPAP machine, maintaining equipment, and dealing with power requirements creates ongoing friction. Bed partner complaints about noise or the appearance of the mask contribute to social pressure against use. Many patients describe CPAP as something they know they should use but find too burdensome to use consistently.

The consequence of non-adherence is that millions of Americans with diagnosed OSA go untreated or undertreated, continuing to experience the cardiovascular, metabolic, and neurocognitive harm of nightly oxygen deprivation and sleep fragmentation. Untreated moderate to severe OSA is associated with a two to four times increased risk of hypertension, a two to three times increased risk of stroke, significantly elevated risk of atrial fibrillation, and increased motor vehicle accident risk. For patients who cannot or will not use CPAP consistently, tirzepatide offers a genuinely new path to reducing these risks.

Can Tirzepatide Actually Replace CPAP?

The question of whether tirzepatide can replace CPAP is nuanced and depends on the individual patient's response. In the SURMOUNT-OSA trial, approximately 43 to 52 percent of tirzepatide-treated participants achieved an AHI below 15, meaning they no longer met criteria for moderate or severe OSA. For these patients, CPAP may genuinely no longer be needed — although continued monitoring is essential because weight regain could restore the airway obstruction. A subset achieved AHI below 5, effectively resolving their sleep apnea entirely.

However, approximately half of participants, while experiencing significant improvement, continued to have an AHI above 15 — meaning they still had moderate or severe OSA despite substantial weight loss. For these patients, CPAP remains necessary, although at lower pressure settings that are typically more comfortable and easier to tolerate. The combination of tirzepatide plus CPAP may actually be the optimal approach for many patients: tirzepatide reduces the severity of underlying disease while CPAP manages the residual obstruction.

Sleep medicine specialists generally recommend the following approach: start tirzepatide while continuing CPAP use, reassess with a follow-up sleep study after 6 to 12 months of treatment and significant weight loss, reduce CPAP pressure if auto-titrating technology or a repeat titration study indicates lower pressures are sufficient, and consider CPAP discontinuation only if the follow-up sleep study shows AHI below 5 in the absence of CPAP. This structured approach protects patients from the cardiovascular risks of untreated OSA during the transition period. For information about sleep improvements beyond apnea reduction, see our article on GLP-1 and sleep quality.

Who Qualifies and How to Get Started

Eligibility for Zepbound for sleep apnea requires documented moderate to severe OSA (AHI 15 or higher) confirmed by a sleep study, plus a BMI of 30 or higher. Patients must have a sleep study on file — either a laboratory polysomnography or an FDA-cleared home sleep apnea test — documenting the AHI. If your most recent sleep study is more than 2 years old, many providers will recommend a repeat study to establish a current baseline before starting treatment.

The prescribing pathway typically involves a sleep medicine specialist who diagnoses and documents the OSA, and either the sleep specialist or an obesity medicine provider who prescribes tirzepatide. Some patients may already be on tirzepatide for weight management or diabetes and can work with their sleep specialist to document the OSA indication. The standard tirzepatide dose escalation applies: starting at 2.5 mg weekly and escalating every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg depending on tolerability and response.

Insurance coverage for Zepbound under the OSA indication is evolving. Some insurers have been more receptive to covering tirzepatide for OSA than for obesity alone, because OSA is classified as a disease with clear cardiovascular consequences rather than a lifestyle condition. Prior authorization typically requires documentation of the sleep study results, BMI, and often evidence of CPAP intolerance or non-adherence. Patients should work with their provider's prior authorization team to navigate coverage. For general information on starting tirzepatide, see our article on getting started with tirzepatide.

The Combination Approach: Tirzepatide Plus CPAP

For many patients, the optimal strategy is not tirzepatide instead of CPAP but tirzepatide alongside CPAP, with the goal of eventually reducing or eliminating CPAP dependence. This combination approach offers several advantages. CPAP provides immediate, complete protection against apnea events from the first night of use, while tirzepatide's benefits develop gradually over months as weight loss progresses. During the treatment period, CPAP ensures that the patient is not exposed to the cardiovascular risks of untreated OSA while waiting for the medication to take effect.

As weight decreases and upper airway anatomy improves, CPAP pressure requirements typically decrease. Patients using auto-titrating CPAP (APAP) devices will notice that the machine automatically adjusts to lower pressures as their OSA severity improves. This lower pressure is generally more comfortable and easier to tolerate, which can actually improve CPAP adherence in patients who previously struggled with high-pressure discomfort. Some patients who were completely CPAP-intolerant find that after 6 months of tirzepatide treatment, they can now tolerate CPAP at the lower pressures required — creating a better safety net for managing residual OSA.

The long-term consideration with any medication-based OSA treatment is durability. If a patient discontinues tirzepatide and regains weight, their OSA severity is likely to return. This raises the question of whether tirzepatide use for OSA needs to be indefinite. Current clinical guidance suggests that patients who achieve OSA resolution on tirzepatide should continue the medication to maintain weight loss and OSA control. If discontinuation is necessary, a follow-up sleep study should be performed 3 to 6 months after stopping to assess whether OSA has recurred. For broader context on treatment duration, see our overview of tirzepatide long-term use, and for understanding weight maintenance strategies, review our guide on maintaining weight loss after GLP-1 therapy.